Fractyl Laboratories

Fractyl Laboratories is developing a device-based procedure that resurfaces a section of the small intestine, the duodenal mucosa, which reduces liver insulin resistance in type 2 diabetic patients. This procedure can delay the need for injected insulin and allow patients to continue oral therapy.